Academic founders discovered preclinical breakthrough but needed help translating these findings into therapeutic devices suitable for long-term, daily use in patients affected by Alzheimer’s disease. Product designed with deep understanding of user experience and efficient clinical deployment and support for use in the home. Treatment effects demonstrated in multiple prospective Phase 2 clinical studies. Secured FDA Breakthrough Device designationand being evaluated in a pivotal trial.